Table 1 Medicines identified as potential MES candidates since introduction of formal MES policy in January-2011 [35]
Medicinea | MES |
|---|---|
Ipilimumab for metastatic melanoma (2012) | • Pay for performance with rebates payable should 2 year overall survival rates in real world clinical practice in Australia not align with clinical trial data |
Ivacaftor for cystic fibrosis (2014) | • Pay for performance with rebates applicable for patients subsequently assessed as non-responders |
Eculizumab for atypical haemolytic uraemic syndrome (2014) | • Pay for performance with rebates applicable for patients who do not achieve an agreed clinical outcome over an agreed time periods |
Trametinib for metastatic melanoma (2014) | • Pay for performance with rebates applicable should trametinib fail to deliver claimed benefits |
Crizotinib for non-small cell lung cancer (2014) | • Pay for performance with rebates applicable should crizotinib fail to deliver claimed benefits |
Pembrolizumab for metastatic melanoma (2015) | • PBS list with provision for future clinical trial evidence to support a potential price increase |
Nivolumab for non-small cell lung cancer (2016) | • PBS list with provision of future evidence to confirm effectiveness of nivolumab in NSCLC patients ≥75 years of age |